

TECHNOLOGY MARKETING AND TECHNOLOGY TRANSFER

SATURDAY, 21 JANUARY 2023

BY PRADNYA ARADHYE, RTTP

SENIOR SPECIALIST-INNOVATION MANAGEMENT

VENTURE CENTER, PUNE

OUTLINE

- TECHNOLOGY MARKETING
 - What is technology marketing?
 - Why is it important?
 - Where does it fit in the scheme of technology transfer?
 - How to go about it?
- TECHNOLOGY TRANSFER/ LICENSING
 - Basics of technology licensing
 - Types of licenses
 - Anatomy of a license agreement
 - Examples of licensing from Indian R&D institutes

WORKFLOW OF TECHNOLOGY COMMERCIALIZATION



WHAT IS TECHNOLOGY MARKETING?

- TECHNOLOGY MARKETING IS NOT LIKE MARKETING A PRODUCT AND DOING SALES.....

THEN

- WHAT IS IT?
 - It is putting right information..... in the right hands..... at the right time.

IMPORTANCE OF TECHNOLOGY MARKETING

- Technology /IP does not sell or license itself..... (even "good" a technology).
- Technology transfer without technology marketing....Is like one hand clapping.

TWO WAYS OF TECH MARKETING

PASSIVE MARKETING

- Shot gun approach (non-targeted, mass reach)
- Put out Tech Brief on web (hoping somebody finds it)
 - Websites
 - Social media
 - Marketplaces/ portals

ACTIVE MARKETING

- Rifle firing (target oriented reach)
- Targeted tech brief outreach
 - Carefully selected contacts
 - Carefully selected companies
- Dedicated marketing campaign

PASSIVE MARKETING

- Listing on your own assets (technology listing) website
- Listing on various available portals like: AUTM Innovation Marketplace (AIM), Flintbox etc
- Social media publicity

PORTALS

- Various portals available to list technologies:
 - AUTM Innovation marketplace
 - Flintbox
 - Tech Transfer Online
 - Own website
 - University/ Institute websites

ACTIVE MARKETING

- Selecting and reaching out to companies/ industries who would be interested after doing thorough research
 - Ask the inventor (critical inputs)
 - His/ her students
 - Any lead from the industry
 - Founded on person to person contacts
 - Going to conferences/ exhibitions/ trade shows
 - Running dedicated campaigns for a particular technology: For e.g Technology showcases.
 - IT IS ALL ABOUT NETWORKING !!

THE 3 R's OF TECH MARKETING

- THE "RIGHT" INFORMATION
- IN THE "RIGHT" HANDS
- AT THE "RIGHT" TIME

THE “RIGHT” INFORMATION

- Initially less is more: start with non-confidential discussion
- Define the innovation
 - Precisely
 - How does it work?
 - Its benefit over other existing technologies
 - Substantiate with data
- IP and tangible property status
- Stage of development
- Marketing documents: tech briefs, video, photographs etc

THE “RIGHT” HANDS

- Obvious company/ technology fits
- Non-obvious company/ technology fits
- Initial contacts: decision makers (VP, R&D head, marketing head, open innovation)
- Conferences, trade shows
- Technology brokers
- Scanning trade journals
- Other media

THE “RIGHT” TIME

- It is really difficult to predict the “right” time for any given technology (but priority date of the patent could be the starting point for making the decision).
- Look for obvious strategic positioning of the technology
 - Entry/ forays in to new market
 - New product in the existing market
 - Expanding current product portfolio

MARKETING DOCUMENTS

- THE TECHNOLOGY BRIEF
- OTHER MARKETING COLLATERALS
 - Images/ flyers/ posters
 - Detailed report
 - Videos



Technology Spotlight

 **TechEx.in**
Tech Transfer Hub at Venture Center
Supported by NBM - BIRAC

Deployable Toilet System: Toilets for a non-sewer system

Vishwakarma University has developed an affordable toilet system which is pathogen and odor free. The system is modular and easy to assemble on-site.

Features

- Modular, separable and easy to assemble Toilet system
- Filtration unit for recycling of waste water to flush tank
- Toilet Pot developed from Electronic Waste (e-waste) material
- Cost effective



Technology Readiness Level **6**
System demonstration in real world

Seeking Licensee

Contact Us: Email: tto@venturecenter.co.in | Ph: +91 7410045655

THE TECHNOLOGY BRIEF

Technical Brief

Anakinra Biosimilar

About Anakinra

Anakinra, sold by Swedish Orphan Biovitrum, under the brand name Kineret, is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra), that can reduce the activity of interleukin-1, a key driver of inflammation in autoimmune and autoinflammatory diseases. It is used in rheumatoid arthritis as a second in line treatment to a Disease Modifying Anti Rheumatic Drug, in addition to treating Still's disease, Neonatal-onset multi-system inflammatory disease, and more. However, treatment costs remain high, with \$1194 (for 4.69 ml) and \$3811 (for 18.76ml).

Technology Offering

- Clone, upstream and downstream process for producing biosimilar Anakinra
- Soluble expression of Anakinra eliminating in-vitro refolding step
- Purification process involving novel multimodal chromatographic purification steps > 2X improvement in productivity
- Time and cost effective expression avoiding in-vitro refolding of protein
- Soluble protein expression > 1gm/L of fermentation broth


Market Potential

Nearly 4% of the world's population is affected by one of more than 80 different autoimmune diseases, rheumatoid arthritis being one of the most common. However, very few companies seem to be working on developing biosimilars of the molecule. The biosimilar is also currently being tested for newer indications such as COVID.

Current Technology Status

- Development of Hypotheses and Experimental Designs Done
- Non-clinical *in-vitro* studies: Physicochemical characterization for Biosimilarity Done
- Non-clinical *in-vitro* studies: Functional characterization for Biosimilarity Done

Selected Biosimilarity Data



TECHNOLOGY TRANSFER/ LICENSING

GETTING STARTED

STEPS TO GET STARTED AFTER LEAD IS GENERATED

Initial interactions (email, calls etc)

Discussion becomes a term sheet

Deal structure

If serious interest, follow with a personal meeting


Interest begins to solidify

Financial terms

Initial discussion non-confidential

Later discussion confidential/ sign NDA

Deal closure, signing, Upfront fee



WHAT IS BEING TRANSACTED?

SOURCES OF VALUE IN TECHNOLOGY TRANSFER

- Knowhow (with presumed Freedom to Operate)
- Right to exclude others from practicing the art (valid patent rights) → Source of sustainable, competitive advantage !
- Research and technical support for validating, scale-up, valorizing knowhow/patent rights and commissioning.

QUICK INTRODUCTION TO IP

NO DISCLOSURE

- TRADE SECRET: NOT PUBLICLY DISCLOSED. INFORMATION ACCESS CONTROLLED BY CDA/NDA.

DISCLOSURE + FORMAL RIGHTS

- PATENT: PUBLIC DISCLOSURE. RIGHT TO EXCLUDE OTHERS FOR 20 YEARS.
- INDUSTRIAL DESIGN
- COPYRIGHT
- TRADEMARK
- PLANT VARIETIES
- OTHERS (CIRCUIT LAYOUTS, GEOGRAPHICAL INDICATIONS)

Courtesy: Dr Premnath V, Venture Center

TECHNOLOGY LICENSING BASICS

Following slides are from talk by Dr Ashley Stevens

The image shows a screenshot of a video player interface. The main content is a presentation slide with the following details:

- Top Left:** Venture Center logo
- Top Center:** AIM PRIME Program
- Top Right:** AIMprime logo
- Title:** Session 26 : In/out-licensing:
Collaborating with academic institutes
- Date:** 11th Aug | 5:00 pm IST
- Logos (Initiative of):** NITI Aayog, AIM (Aatmanirnava Innovation Mission), VENTURE CENTER
- Logos (Implemented by):** BILL & MELINDA GATES Foundation
- Logos (Supported by):** Govt of India (Ministry of Science and Technology)
- Logos (Catalyzed by):** PUNE KNOWLEDGE CENTER, AIMprime

At the bottom of the slide, there is a video player control bar with icons for play, pause, volume, and progress (0:03 / 2:08:03). Below the control bar, a small note states: "Made available under CC BY-NC-SA 4.0 license. Please attribute AIM PRIME, <https://primeprogramme.org>".

Text below the slide: Session 26 : In/out-licensing: Collaborating with academic institutes by Dr. Ashley Stevens

https://www.youtube.com/watch?v=y_hzqim7bSU

But WHY Does Someone License Something?

- ❑ Because they can't or won't develop a technology
 - ❑ University Not part of the mission
 - ❑ Small company Inadequate resources to take to market
 - ❑ Invention may not be sufficient to market a product
 - ❑ Platform technology, needs additional inventions to productize
- ❑ They do a deal whereby someone else bears the majority of the risk and receives the majority of the reward
 - ❑ The inventor / licensor receives part of the reward



© 2019 Ashley J. Stevens All Rights Reserved. Do Not Copy or Modify



Types of Licenses

In-Licensing

- ❑ Acquiring the right to develop and sell a product
 - ❑ Enabling license – patents + know-how
 - ❑ Freedom to operate – route through toll gates erected by blocking patents

Out-Licensing

- ❑ Granting rights to intellectual property to others
 - ❑ Enabling license – giving up a product to someone with more resources
 - ❑ Freedom to operate – extracting value from a platform technology

Cross-Licensing

- ❑ Trading IP rights
 - ❑ Mutual elimination of road blocks
 - ❑ Competitive or non-competitive products



Where is Value Extracted in a License?

- Upfront fee
- Ongoing pre-commercial payments
 - Patent costs
 - Milestone payments
 - Annual Minimum Royalties
- Research collaboration and support
- Sublicense income sharing
- Earned royalties



© 2019 Ashley J. Stevens All Rights Reserved. Do Not Copy or Modify



License Agreement Outline

- ❑ Recitals
- ❑ Definitions
- ❑ License Grant
- ❑ Fees, Royalties, & Payments
- ❑ Patent Prosecution & Infringement
- ❑ Obligations of the Parties
- ❑ Representations & Warranties
- ❑ Indemnification & Insurance
- ❑ Confidentiality & Publication
- ❑ Term & Termination
- ❑ Miscellaneous



© 2019 Ashley J. Stevens All Rights Reserved. Do Not Copy or Modify



EXAMPLES OF TECH LICENSING FROM INDIA

SUCCESSFUL TT FROM INDIAN R&D INSTITUTES

CSIR-IMTECH's know-how on thrombolytics: natural streptokinase (SK) – the first generation of CSIR's clot busters


Source: [CSIR-IMTECH website](#)



Transferred to M/S Cadila Pharma. Ltd., Ahmedabad in 2001

CSIR-CDRI and CSIR-CIMAP jointly developed EMAL α - β Arteether - Schizontocidal Anti-malarial for Cerebral & Chloroquine Resistant Malaria


Source: [CSIR website](#)



The technology was Licensed to M/s 29 Themis Medicare Ltd, Mumbai

LEARNINGS

WHAT IT TAKES FOR A DEAL TO HAPPEN?



- It is much harder than you expect
- It is difficult to get people's attention (even for a good technology)
- **ALWAYS** be marketing: key to success

What has worked for us?

- Personal contacts
- Networks
- Leads from the inventor

CREDITS

The information in the slides is adapted from the presentations by Dr Richard Cahoon, Dr Ashley Stevens and Dr Premnath V.

Contact:

Ms Pradnya Aradhye

Phone: +91-8805009010

Email: pradnya@venturecenter.co.in